Skip to main content

Seagen, Inc. (SGEN)

NASDAQ: SGEN · IEX Real-Time Price · USD
170.20
-1.23 (-0.72%)
After-hours:Oct 22, 2021 5:34 PM EDT
171.43
-2.47 (-1.42%)
At close: Oct 22, 4:00 PM
Market Cap31.64B
Revenue (ttm)2.38B
Net Income (ttm)597.27M
Shares Out181.63M
EPS (ttm)3.21
PE Ratio53.49
Forward PE217.39
Dividendn/a
Ex-Dividend Daten/a
Volume380,059
Open174.47
Previous Close173.90
Day's Range170.79 - 175.00
52-Week Range133.20 - 202.60
Beta0.82
AnalystsBuy
Price Target189.00 (+10.2%)
Est. Earnings DateOct 28, 2021

About SGEN

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of metastatic urothelial cancers; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. I...

IndustryBiotechnology
Employees2,092
Stock ExchangeNASDAQ
Ticker SymbolSGEN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 20 analysts, the average rating for Seagen stock is "Buy." The 12-month stock price forecast is 189.00, which is an increase of 10.25% from the latest price.

Price Target
$189.00
(10.25% upside)
Analyst Consensus: Buy

News

Earnings Preview: Seattle Genetics (SGEN) Q3 Earnings Expected to Decline

Seattle Genetics (SGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 day ago - Zacks Investment Research

Seagen's (SGEN) Cancer Portfolio Strong, Stiff Rivalry a Worry

Seagen (SGEN) focuses on improving sales of its marketed drugs that are approved for different types of cancer indications. Stiff competition in the target market remains a woe.

1 week ago - Zacks Investment Research

3 Biotech Stocks You Can Buy and Hold for the Next Decade

Balance risk and reward with these proven drugmakers.

Other symbols:REGNVRTX
1 week ago - The Motley Fool

Astellas and Seagen Complete Enrollment in EV-103 Trial Cohort K Combining PADCEV® (enfortumab vedotin-ejfv) with Pem...

TOKYO and BOTHELL, Wash., Oct. 12, 2021 /PRNewswire/ -- Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D.

1 week ago - PRNewsWire

Seagen to Host Conference Call and Webcast Discussion of Third Quarter 2021 Financial Results on October 28, 2021

BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) today announced that it will report its third quarter 2021 financial results on Thursday, October 28, 2021 after the close of U.S. financial m...

2 weeks ago - Business Wire

Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates

Following a mixed month for regulatory approvals, biotech investors now turn toward a month of plenty as far as Food and Drug Administration decisions are concerned. Four new molecular entities, or NMEs...

Other symbols:GMABINCYTAK
3 weeks ago - Benzinga

Seagen (SGEN) Completes Enrollment in Colorectal Cancer Study

Seagen (SGEN) enrolls the last patient in the phase II MOUNTAINEER study evaluating Tukysa in combination with Herceptin, and as a single agent for treating HER2-positive metastatic colorectal cancer.

3 weeks ago - Zacks Investment Research

Seagen Announces Last Patient Enrolled in Phase 2 MOUNTAINEER Trial Evaluating TUKYSA® (Tucatinib) Regimen in HER2-Po...

BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Announces Last Patient Enrolled in Phase 2 MOUNTAINEER Trial Evaluating TUKYSA® Regimen in HER2-Positive Metastatic Colorectal Cancer

3 weeks ago - Business Wire

Japan's MHLW Approves PADCEV® (enfortumab vedotin) for Advanced Urothelial Cancer

TOKYO and BOTHELL, Wash., Sept. 27, 2021 /PRNewswire/ -- Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D.

3 weeks ago - PRNewsWire

Seagen (SGEN) Gets Early FDA Nod for Tivdak in Cervical Cancer (Revised)

The FDA grants accelerated nod to Seagen (SGEN) and Genmab's Tivdak for treating adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy.

1 month ago - Zacks Investment Research

Seagen (SGEN) Gets Early FDA Nod for Tivdak in Cervical Cancer

The FDA grants accelerated nod to Seagen (SGEN) and Genmab's Tivdak for treating adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy.

1 month ago - Zacks Investment Research

FDA Gives Accelerated Approval to Seagen - Genmab's ADC In Cervical Cancer

The FDA handed an accelerated approval to Seagen Inc (NASDAQ: SGEN) and Genmab A/S' (NASDAQ: GMAB) Tivdak (tisotumab vedotin-tftv, or TV). The nod comes for second-line patients with recurrent or metast...

Other symbols:GMAB
1 month ago - Benzinga

Seagen to Host Conference Call and Webcast Discussion on September 21, 2021 to Discuss TIVDAK™ (tisotumab vedotin-tft...

BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) will host a conference call and webcast on Tuesday, September 21, 2021 to discuss the U.S. Food and Drug Administration approval of TIVDAK™ (t...

1 month ago - Business Wire

Seagen, Genmab Present Tisotumab Vedotin Combo Data In Cervical Cancer

Seagen Inc (NASDAQ: SGEN) and Genmab A/S (NASDAQ: GMAB) have interim data from two Phase 1b/2 innovaTV 205 trial cohorts. The trial is evaluating its antibody-drug conjugate tisotumab vedotin (TV) in re...

Other symbols:GMAB
1 month ago - Benzinga

7 Stocks To Buy To Bet on Underappreciated CEOs

We hear plenty of stories about overpaid CEOs. Here are seven stocks to buy whose CEOs aren't but still manage to deliver for shareholders.

1 month ago - InvestorPlace

3 Top Healthcare Stocks to Buy for September

Catalysts are on the horizon for these bargain stocks.

Other symbols:TDOCVRTX
1 month ago - The Motley Fool

Seagen to Present at the Morgan Stanley 19th Annual Global Healthcare Conference

BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) today announced that management will participate in a virtual fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on ...

1 month ago - Business Wire

Seagen to Highlight Research From 16 Presentations Across Multiple Tumor Types at ESMO 2021

BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) today announced data and trials in progress from its diverse and growing portfolio of marketed and investigational therapies will be presented...

1 month ago - Business Wire

Which Biotech Stock Will Shock the Market in 2022?

Over the last few years, three tiny biotechs emerged out of nowhere to give amazing returns to early investors. Which biotech might pull off a similar feat in 2022?

1 month ago - The Motley Fool

Seagen Bets On China's ADC In $2.6B Cancer Deal

Seagen Inc (NASDAQ: SGEN) and RemeGen Co Ltd have entered into an exclusive worldwide licensing agreement to develop and commercialize disitamab vedotin. For $200 million upfront, Seagen is getting ex-A...

2 months ago - Benzinga

Seagen and RemeGen Announce Exclusive Worldwide License and Co-Development Agreement for Disitamab Vedotin

BOTHELL, Wash. & YANTAI, China--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN), a world leader and pioneer in antibody-drug conjugate (ADC) therapies, and RemeGen Co., Ltd. (9995.HK), a leading innovative ...

2 months ago - Business Wire

Seagen (SGEN) Q2 Earnings Beat Estimates, Revenues Surge Y/Y

Seagen (SGEN) reports narrower-than-expected loss for the second quarter of 2021 while revenues beat estimates.

2 months ago - Zacks Investment Research

Seattle Genetics (SGEN) Reports Q2 Loss, Tops Revenue Estimates

Seattle Genetics (SGEN) delivered earnings and revenue surprises of 22.95% and 9.24%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Seagen Reports Second Quarter 2021 Financial Results

BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq:SGEN) today reported financial results for the second quarter and six months ended June 30, 2021. The Company also highlighted ADCETRIS® (brentuximab...

2 months ago - Business Wire